SEC Tracker
Get the app

Repligen RGEN

Repligen completes acquisition of BioLife

Form
8-K
Filed
Importance
Major
  1. Completed acquisition of BioLife on Oct 6, 2026
  2. BioLife shareholders received $11.25 cash and 0.1442 shares of Repligen stock
  3. BioLife no longer listed on Nasdaq after merger
  4. Repligen expects to discuss financial impact in Q3 2026 earnings call

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Repligen files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  2. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  3. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025
  4. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  5. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025